Eyepoint Inc.
- Address
- 480 Pleasant Street
Sponsor Overview
Specializations
Retinal Disease Research
Eyepoint Inc. focuses on clinical research in retinal disorders affecting central vision, with studies centered on diabetic macular edema and wet age-related macular degeneration.
- Diabetic Macular Edema
- Wet Age-Related Macular Degeneration
- Macular pathology
Its research activity is concentrated in ophthalmology and the treatment of vision-threatening macular disease.
Vision Preservation and Visual Function
The sponsor’s trials are designed around outcomes in best corrected visual acuity, reflecting a strong interest in preserving and improving central visual function in patients with retinal disease.
- Best corrected visual acuity
- Central vision
- Visual impairment
These studies place emphasis on clinical endpoints relevant to day-to-day visual performance in ophthalmic care.
Intravitreal Therapeutics
Eyepoint Inc. is active in research involving intravitreal treatment approaches for retinal disease, including sustained ocular delivery strategies used in posterior segment disorders.
- Intravitreal inserts
- Ocular drug delivery
- Posterior segment therapy
Its therapeutic interest lies in treatments intended for chronic management of retinal vascular disease.
Anti-VEGF Comparator Studies
The sponsor’s trials compare its retinal therapy with established anti-vascular endothelial growth factor treatment, indicating a focus on clinically relevant alternatives in retina specialist practice.
- Aflibercept
- Anti-VEGF therapy
- Retinal vascular disorders
Research activity is directed toward treatment options for patients with macular edema and neovascular retinal disease.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 3 Randomized Study Comparing the Efficacy of Vorolanib to Aflibercept in Participants with Diabetic Macular Edema |  Czechia Germany Hungary | Recruiting |
| A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 to Aflibercept in Participants with Diabetic Macular Edema | Germany Poland Slovakia | Recruiting |
| Phase 3 Randomized Double-Masked Study of Vorolanib (EYP-1901) Versus Aflibercept in Patients with Wet Age-Related Macular Degeneration | Czechia Germany Hungary Poland Slovakia | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 39 sites across their trial portfolio.
Therapeutic Focus
- 1.Eye Diseases3 trials138 other sponsors
Partnered Research Centres
39 centres- Address
- Ostrovskeho 253/3, Smichov, 150 00 Prague
- Address
- Maglodi Ut 89-91, Kerulet, 1106 Budapest
- Address
- Vaci Ut 76, Kerulet, 1133 Budapest
- Address
- Langenbeckstrasse 1, Oberstadt, 55131 Mainz
- Address
- Podmaniczky Utca 109, 1062 Budapest
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Eyepoint Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.